# ClearPoint Neuro, Inc. (CLPT) · Edgar & Edgarette company card

> ClearPoint Neuro (CLPT) grew revenue 17.8% in FY2025 to $37 million, operating margin -65.4% against a 1.2% median for surgical & medical instruments & apparatus, equity 28.7% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1285550 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/CLPT) · [JSON](https://www.pops4.com/boards/company/CLPT.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $37M |
| Revenue growth, 1 year | 17.8% |
| Revenue growth per year | 22.7% |
| Operating margin | -65.4% (prior year -62.9%) |
| Net margin | -69.1% |
| Operating cash flow | −$24M |
| Capital spending | $522,000 |
| Free cash flow | −$24M |
| Cash | $46M |
| Long-term debt | $49M |
| Total assets | $98M |
| Total equity | $28M |
| Equity ÷ assets | 28.7% |
| Return on equity | -91.1% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -4.93 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Beneish M: -1.76 (above the −1.78 line)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -65.4% in FY2025; revenue is hard to predict: its 80% range is ±35%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $37.0M (FY2025), total debt $49.1M. Experience: revenue up 17.8% on the year, up 22.7% a year over 4 years; operating margin -65.4%, down from -62.9%. Soundness: equity 28.7% of assets, return on equity -91.1%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $29.9M and $62.6M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $28.5M to $65.9M. A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -65.4% against a 1.2% median; growth 17.8% against 11.6%.

Range logged 2026-11-01, receipt 3b8a63ef9df7f517, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-05-21 ([filing](https://www.sec.gov/Archives/edgar/data/1285550/000119312526234571/0001193125-26-234571-index.htm))

## Recent filings

- 8-K · filed 2026-11-18 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1285550/000119312526467272/0001193125-26-467272-index.htm)
- 10-Q · filed 2026-10-28 · [filing](https://www.sec.gov/Archives/edgar/data/1285550/000119312526436412/0001193125-26-436412-index.htm)
- 8-K · filed 2026-10-28 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1285550/000119312526436125/0001193125-26-436125-index.htm)
- 10-Q · filed 2026-08-03 · [filing](https://www.sec.gov/Archives/edgar/data/1285550/000119312526330842/0001193125-26-330842-index.htm)
- 8-K · filed 2026-08-03 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1285550/000119312526330541/0001193125-26-330541-index.htm)
- 8-K · filed 2026-05-21 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1285550/000119312526234571/0001193125-26-234571-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001285550.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1285550

## Cite

POPS4, Edgar & Edgarette: ClearPoint Neuro, Inc. (CLPT) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/CLPT. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

